European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect| Merck & Co. (NYSE: MRK) | Delayed: 128.66 +3.21 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $65.46 | |||
| Open | $125.83 | 52 Week Low | $47.97 | |||
| Day High | $128.78 | P/E | 87.52 | |||
| Day Low | $125.83 | EPS | $1.47 | |||
| Volume | 18,891,511 | |||||
